SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Freedom Meditech, Inc. today announced it has received official notification from the United States Patent and Trademark Office that the company has been granted a key patent providing the protection of intellectual property covering the ClearPath DS-120 device and method of use.
This newly issued patent, U.S. patent No. 13/291,072, allows for claims on the apparatus and the method which in combination enables diagnostic efficacy for optimal performance with a minimum of error for measuring autofluorescence in the crystalline lens of the eye using a blue light source. The ClearPath DS-120 measures the presence of fluorescent advanced glycation end products, or AGEs, in the crystalline lens of the eye. Studies have shown that AGEs accumulate over time and are correlated with uncontrolled glucose indicative of diabetes.
“This patent demonstrates the innovative nature of the ClearPath DS-120 for the rapid, six second detection of autofluorescence in the lens of the eye,” said Keith D. Ignotz, president and CEO of Freedom Meditech. “ClearPath deploys a non-invasive, painless point of care method for accurately measuring autofluorescence to detect structural changes to biological tissue, such as the accumulation of AGEs in the lens of the eye. Studies suggest that elevated AGEs are directly correlated to uncontrolled glucose -- the hallmark of diabetes.”
About ClearPath DS-120
The ClearPath DS-120 Lens Fluorescence Biomicroscope is cleared by FDA and has the CE mark and Canadian Device Establishment license as a tool for the measurement of autofluorescence by scanning the crystalline lens of the eye with a blue light. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycation end products (AGEs) which accumulate as a result of the aging process and the presence of systemic disease.
The ClearPath scan is pain free, takes just six seconds and produces an immediate, quantitative result available to the patient and health care provider. Unlike some eye exams, the scan does not require dilation. The ClearPath is completely non-invasive and does not require a blood draw to produce a result.
About Freedom Meditech
Freedom Meditech, Inc. is a medical device company focused on the commercialization of novel ophthalmic technologies for the detection of disease and management of patient health. The company’s first product, the ClearPath DS-120, is a non-invasive tool for the measurement of autofluorescence in the eye, has been cleared by the FDA, and has obtained the CE mark and a Canadian Establishment license. I-SugarX is the company’s second product currently in development as a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes, to replace the finger-prick technologies currently in the market. The company maintains corporate and engineering operations in San Diego, CA with supporting research and development activities throughout the state of Ohio. For more information, visit www.freedom-meditech.com or find us on Twitter, Facebook and LinkedIn.
Investor Contact:
Sharad Mishra
Freedom Meditech, Inc.
(858) 638-1433 x. 223
smishra@freedom-meditech.com
SOURCE Freedom Meditech, Inc.
Help employers find you! Check out all the jobs and post your resume.
